GSA Capital Partners LLP Takes $1.48 Million Position in Castle Biosciences, Inc. (NASDAQ:CSTL)

GSA Capital Partners LLP purchased a new position in shares of Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 51,827 shares of the company's stock, valued at approximately $1,478,000. GSA Capital Partners LLP owned 0.19% of Castle Biosciences at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. Principal Financial Group Inc. increased its position in Castle Biosciences by 2.7% in the third quarter. Principal Financial Group Inc. now owns 1,538,520 shares of the company's stock worth $43,879,000 after buying an additional 40,377 shares during the last quarter. Vanguard Group Inc. increased its position in Castle Biosciences by 2.2% in the first quarter. Vanguard Group Inc. now owns 1,494,176 shares of the company's stock worth $33,096,000 after buying an additional 32,695 shares during the last quarter. Dimensional Fund Advisors LP increased its position in Castle Biosciences by 8.1% in the second quarter. Dimensional Fund Advisors LP now owns 809,934 shares of the company's stock worth $17,631,000 after buying an additional 60,675 shares during the last quarter. Renaissance Technologies LLC increased its position in Castle Biosciences by 47.3% in the second quarter. Renaissance Technologies LLC now owns 301,500 shares of the company's stock worth $6,564,000 after buying an additional 96,800 shares during the last quarter. Finally, Acadian Asset Management LLC grew its position in shares of Castle Biosciences by 33.0% in the second quarter. Acadian Asset Management LLC now owns 280,497 shares of the company's stock valued at $6,101,000 after purchasing an additional 69,673 shares in the last quarter. 92.60% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on CSTL shares. Scotiabank lifted their price target on Castle Biosciences from $37.00 to $44.00 and gave the company a "sector outperform" rating in a research report on Wednesday, November 6th. KeyCorp lifted their price target on Castle Biosciences from $28.00 to $36.00 and gave the company an "overweight" rating in a research report on Tuesday, November 5th. Stephens restated an "overweight" rating and set a $37.00 target price on shares of Castle Biosciences in a research report on Tuesday, August 6th. Lake Street Capital boosted their target price on Castle Biosciences from $34.00 to $40.00 and gave the stock a "buy" rating in a research report on Tuesday, November 5th. Finally, Canaccord Genuity Group lifted their price target on Castle Biosciences from $35.00 to $42.00 and gave the stock a "buy" rating in a research note on Tuesday, October 29th. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average target price of $37.88.

Castle Biosciences Trading Down 1.4 %

NASDAQ:CSTL traded down $0.44 during mid-day trading on Thursday, reaching $31.36. 113,210 shares of the company's stock traded hands, compared to its average volume of 324,675. Castle Biosciences, Inc. has a 12-month low of $16.97 and a 12-month high of $35.84. The firm has a market capitalization of $878.39 million, a price-to-earnings ratio of 159.01 and a beta of 0.99. The company has a debt-to-equity ratio of 0.02, a current ratio of 7.78 and a quick ratio of 7.64. The company has a 50 day moving average price of $31.13 and a 200-day moving average price of $26.18.

Castle Biosciences (NASDAQ:CSTL - Get Free Report) last posted its earnings results on Monday, November 4th. The company reported $0.08 earnings per share for the quarter, topping analysts' consensus estimates of ($0.06) by $0.14. Castle Biosciences had a return on equity of 1.47% and a net margin of 1.95%. The firm had revenue of $85.78 million for the quarter, compared to the consensus estimate of $78.55 million. During the same quarter in the prior year, the business earned ($0.26) EPS. On average, sell-side analysts predict that Castle Biosciences, Inc. will post -0.08 earnings per share for the current year.

Insider Buying and Selling

In related news, insider Tobin W. Juvenal sold 3,507 shares of the company's stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $35.56, for a total value of $124,708.92. Following the transaction, the insider now directly owns 54,178 shares of the company's stock, valued at approximately $1,926,569.68. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In related news, insider Tobin W. Juvenal sold 3,507 shares of the company's stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $35.56, for a total value of $124,708.92. Following the transaction, the insider now directly owns 54,178 shares of the company's stock, valued at approximately $1,926,569.68. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Derek J. Maetzold sold 986 shares of the company's stock in a transaction that occurred on Friday, October 4th. The shares were sold at an average price of $28.73, for a total value of $28,327.78. Following the completion of the transaction, the insider now directly owns 94,622 shares in the company, valued at $2,718,490.06. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 15,318 shares of company stock worth $478,124 in the last 90 days. Insiders own 7.20% of the company's stock.

About Castle Biosciences

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.